U.S. Foreign Assistance to Central Asia, and More from CRS
One of the features that make Congressional Research Service reports broadly valuable is that they often reflect the privileged access to executive branch information that is enjoyed by CRS, at least in some areas, compared to what an ordinary member of the public can expect. So, for example, a newly updated CRS report on Central Asia provides authoritative tabulations of US foreign assistance to Central Asian countries, broken down by country and by year for the past two decades. Assembling this data independently would be a difficult and time-consuming chore, if it were possible at all. See Central Asia: Regional Developments and Implications for U.S. Interests, updated September 19, 2012. (For a critical assessment of US aid to Central Asia based on data previously published by CRS, see “U.S. Military Aid To Central Asia: Who Benefits?” by Joshua Kucera, September 25.)
Some other new and newly updated reports from the Congressional Research Service that materialized on our website include the following.
Prospects for Democracy in Hong Kong: Results of the 2012 Elections, September 14, 2012
Trafficking in Persons: International Dimensions and Foreign Policy Issues for Congress, updated September24, 2012
Energy Policy: Election Year Issues and Legislative Proposals, September 24, 2012
The Post-9/11 Veterans Educational Assistance Act of 2008 (Post-9/11 GI Bill): Primer and Issues, September 21, 2012
The Committee on Foreign Investment in the United States (CFIUS), updated September 26, 2012
U.S. Public Diplomacy: Legislative Proposals to Amend Prohibitions on Disseminating Materials to Domestic Audiences, September 21, 2012
Mexico: Issues for Congress, updated September 24, 2012
The Eurozone Crisis: Overview and Issues for Congress, updated September 26, 2012
Nuclear weapons budgeting is like agreeing to buying a house without knowing the sales price, the mortgage rate, or the monthly payment.
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.